REX Medical Limited Pharmaceutical Import Profile — New Zealand (DGFT 2022–2026)

Name: REX Medical Limited Pharmaceutical Import Records from India — 2 Products, $4.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

REX Medical Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $4.5M Trade | TransData Nexus

REX Medical Limited

Pharmaceutical Importer · New Zealand · Respiratory Focus · $4.5M Total Trade · DGFT Verified

REX Medical Limited is a pharmaceutical importer based in New Zealand with a total trade value of $4.5M across 2 products in 1 therapeutic categories. Based on 158 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. REX Medical Limited sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

REX Medical Limited — Import Portfolio & Supplier Network

REX Medical Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to REX Medical Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$2.1M	152	100.0%

REX Medical Limited sources from 1 verified Indian supplier across 89 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does REX Medical Limited Import?

Formulation	Value	Ships
Salair no dose counter salbutamol	$135.9K	5
Salair no dose counter	$125.1K	4
Salair no dose countersalbutamol 100mcg	$100.0K	2
Salair no dose counter salbutamol	$78.7K	3
Everet 750MG tablet levetiracetam.	$73.8K	2
Trexate 10 MG methotrexate tablets 10	$70.8K	2
Everet 500MG tablet (levetiracetam). (inv.qty.14526 Pack 6x10s=871560 nos	$67.8K	3
Vasorex 5 MG tablets amlodipine .	$62.2K	3
Tamsulosin 0.4 MG capsules	$50.0K	1
Tamsulosin 0.4 MG capsules	$50.0K	1
Tamsulosin 0.4 MG capsules	$50.0K	1
Everet 1000 MG tablet levetiracetam	$50.0K	1
Siterone 50 cyproterone acetate	$50.0K	1
Everet 500MG tablet levetiracetam.	$50.0K	1
Entecavir rex film coated tablet 0.5MG entecavir 0.5MG	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salbutamol	Respiratory	$4.0M	133	1.2%	12
2	Ipratropium	Respiratory	$532.3K	25	0.5%	11

REX Medical Limited imports 2 pharmaceutical products across 1 categories into New Zealand totaling $4.5M.

REX Medical Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

REX Medical Limited is a 100% New Zealand-owned pharmaceutical company committed to enhancing the health and well-being of New Zealanders. Established in 1995, the company has over 20 years of experience in the pharmaceutical sector, providing a wide range of high-quality and cost-effective pharmaceutical solutions. (rexmedical.co.nz) REX Medical Limited operates under stringent quality standards to ensure that its products and services meet or exceed all regulatory requirements set by Medsafe, New Zealand's Medicines and Medical Devices Safety Authority. (rexmedical.co.nz)

The company's product portfolio is extensive, covering various therapeutic categories, including respiratory inhalers, analgesics, antibiotics, and anti-inflammatories. Notably, REX Medical Limited offers a comprehensive range of respiratory products, such as inhalers and nasal sprays, aimed at managing conditions like asthma and chronic obstructive pulmonary disease (COPD). (rexmedical.co.nz) REX Medical Limited's operations are headquartered in Auckland, New Zealand, with its registered office located at Unit 18, 273 Neilson Street, Onehunga, Auckland, 1061.

2Distribution Network

REX Medical Limited's distribution network is designed to ensure the efficient delivery of pharmaceutical products across New Zealand. The company operates its own licensed pharmaceutical warehousing facility, which serves as a central hub for storing and managing inventory. This facility enables REX Medical Limited to supply products to various distribution outlets, including pharmaceutical wholesalers, pharmacies, hospitals, and supermarkets throughout the country. (rexmedical.co.nz)

While the company's primary focus is on the New Zealand market, REX Medical Limited's strategic sourcing and distribution capabilities suggest potential for expansion into international markets. However, specific details regarding their logistics capabilities and geographic coverage beyond New Zealand are not publicly disclosed.

3Industry Role

REX Medical Limited plays a significant role in New Zealand's pharmaceutical supply chain as a medicine wholesaler. The company is responsible for importing, storing, and distributing a diverse range of pharmaceutical products to various healthcare providers and retailers across the country. By maintaining a comprehensive product portfolio and a robust distribution network, REX Medical Limited ensures the availability of essential medicines to meet the healthcare needs of New Zealanders. (rexmedical.co.nz)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — REX Medical Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

REX Medical Limited's sourcing strategy exhibits a high degree of concentration, with a total import value of $4.5 million USD from India, comprising 158 shipments. The company's portfolio is entirely focused on respiratory products, with the top two products—Salbutamol and Ipratropium—accounting for 100% of the imported products. This indicates a strategic choice to specialize in respiratory therapies, aligning with the company's commitment to enhancing respiratory health in New Zealand.

The exclusive sourcing from a single supplier, CIPLA Limited, for all 158 shipments, suggests a stable and long-term relationship. This concentration may offer benefits such as favorable pricing, consistent product quality, and streamlined logistics. However, it also presents potential risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities.

2Supply Chain Resilience

REX Medical Limited's supply chain resilience is closely tied to its exclusive partnership with CIPLA Limited, a leading Indian pharmaceutical manufacturer. This relationship ensures a consistent supply of respiratory products, which is crucial for meeting the healthcare needs of New Zealanders. However, the lack of alternative suppliers may expose REX Medical Limited to risks associated with supply chain disruptions, such as delays, quality issues, or regulatory changes affecting imports from India.

Importing Pharmaceuticals into New Zealand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for New Zealand

1Regulatory Authority & Framework

In New Zealand, the regulation of pharmaceutical products is overseen by Medsafe, the Medicines and Medical Devices Safety Authority. Medsafe operates under the Medicines Act 1981 and the Medicines Regulations 1984, which provide the legislative framework for the approval, importation, and distribution of medicines in the country. (medsafe.govt.nz)

The approval process for pharmaceutical products involves a comprehensive evaluation to ensure safety, efficacy, and quality. This includes the assessment of clinical trial data, manufacturing processes, and labeling information. For imported medicines, Medsafe requires that products comply with the New Zealand Code of Good Manufacturing Practice (GMP) for Manufacture and Distribution of Therapeutic Goods, which aligns with international standards such as those set by the Pharmaceutical Inspection Co-operation Scheme (PIC/S). (medsafe.govt.nz)

2Import Licensing & GMP

Importing pharmaceutical products into New Zealand requires compliance with specific licensing and certification requirements. Importers must obtain an import license from Medsafe, which involves demonstrating that the imported medicines meet New Zealand's regulatory standards. Additionally, the Medicines Regulations 1984 stipulate that all medicines imported into New Zealand must be securely packed to withstand and protect the contents during transport. (legislation.govt.nz)

REX Medical Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

REX Medical Limited's product strategy focuses on respiratory therapies, particularly inhalers and nasal sprays, to manage conditions like asthma and COPD. This focus aligns with the high prevalence of respiratory diseases in New Zealand and the company's commitment to improving respiratory health. The demand for these products is driven by the need for effective management of chronic respiratory conditions, which are common in the New Zealand population. (rexmedical.co.nz)

By specializing in respiratory products, REX Medical Limited can leverage its expertise to offer tailored solutions that meet the specific needs of patients and healthcare providers. This strategic focus also allows the company to build strong relationships with key stakeholders in the healthcare sector, including hospitals, pharmacies, and healthcare professionals.

2Sourcing Profile

REX Medical Limited's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on respiratory products. The company imports a total of 89 unique formulations, all sourced from a single supplier, CIPLA Limited. This approach ensures consistency in product quality and supply chain management.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — REX Medical Limited

What products does REX Medical Limited import from India?

REX Medical Limited imports 2 pharmaceutical products across 1 categories. Top imports: Salbutamol ($4.0M), Ipratropium ($532.3K).

Who supplies pharmaceuticals to REX Medical Limited from India?

REX Medical Limited sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $2.1M).

What is REX Medical Limited's total pharmaceutical import value?

REX Medical Limited's total pharmaceutical import value from India is $4.5M, based on 158 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does REX Medical Limited focus on?

REX Medical Limited imports across 1 categories. The largest: Respiratory (100.0%).

Get Full REX Medical Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.